1	Human leishmaniasis vaccines: use cases, target population and potential global
2	demand
3	
4	Stefano Malvolti <sup>1</sup> , Melissa Malhame <sup>1</sup> , Carsten Mantel <sup>1</sup> , Epke A. Le Rutte <sup>2</sup> , Paul M.Kaye <sup>3</sup>
5	
6	<sup>1</sup> MMGH Consulting, Zurich, Switzerland
7	<sup>2</sup> Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute,
8	Basel, Switzerland; Department of Public Health, Erasmus MC, University Medical Center
9	Rotterdam, Rotterdam, The Netherlands,
10	<sup>3</sup> York Biomedical Research Institute, Hull York Medical School, University of York,
11	Heslington, York, United Kingdom
12	
13	Corresponding authors: <u>malvoltis@mmglobalhealth.org</u> (ORCID iD: 0000-0003-0146-
14	1127); paul.kaye@york.ac.uk (ORCID iD: 0000-0002-8796-4755)
15	
16	
17	Short title: Analysis of the global demand for leishmaniasis vaccines
18	
19	Keywords: leishmaniasis, visceral leishmaniasis, cutaneous leishmaniasis, post-kala-azar
20	dermal leishmaniasis, vaccine, use cases, demand, forecast
21	
22	

#### 23 Abstract

The development of vaccines against one or all forms of human leishmaniasis remains 24 hampered by a paucity of investment, at least in part resulting from the lack of well-25 evidenced and agreed estimates of vaccine demand. Starting from the definition of 4 main 26 use cases (prevention of visceral leishmaniasis, prevention of cutaneous leishmaniasis, 27 prevention of post-kala-azar dermal leishmaniasis and treatment of post-kala-azar dermal 28 leishmaniasis), we have estimated the size of each target population, focusing on those 29 endemic countries where incidence levels are sufficiently high to justify decisions to adopt a 30 vaccine. We assumed a dual vaccine delivery strategy, including a wide age-range catch-up 31 campaign before the start of routine immunisation. Vaccine characteristics and delivery 32 33 parameters reflective of a target product profile and the likely duration of the clinical 34 development effort were considered in forecasting the demand for each of the four indications. Over a period of 10 years, this demand is forecasted to range from 310-830 35 36 million doses for a vaccine preventing visceral leishmaniasis and 557-1400 million doses for a vaccine preventing cutaneous leishmaniasis under the different scenarios we simulated. In a 37 scenario with an effective prophylactic visceral leishmaniasis vaccine, demand for use to 38 prevent or treat post-kala-azar dermal leishmaniasis would be more limited (over the 10 years 39  $\sim$ 160,000 doses for prevention and  $\sim$ 7,000 doses for treatment). Demand would rise to 40 41 exceed 330,000 doses, however, in the absence of an effective vaccine for visceral leishmaniasis. Because of the sizeable demand and potential for public health impact, a 42 single-indication prophylactic vaccine for visceral or cutaneous leishmaniasis, and even more 43 44 so a cross-protective prophylactic vaccine could attract the interest of commercial developers. Continuous refinement of these first-of-their kind estimates and confirmation of country 45 willingness and ability to pay will be paramount to inform the decisions of policy makers and 46

47 developers in relation to a leishmaniasis vaccine. Positive decisions can provide a much-

- 48 needed contribution towards the achievement of global leishmaniasis control.
- 49

#### 50 Author Summary

The leishmaniases are potentially vaccine-preventable diseases of global importance, yet no 51 vaccines for human use have attained registration. This work sheds lights on the potential size 52 of demand for a human vaccine for the prevention of visceral and cutaneous leishmaniasis as 53 well as for the prevention and treatment of post-kala-azar dermal leishmaniasis. The analysis 54 is grounded in the definition of vaccine use cases which, by transparently defining different 55 applications of the vaccines in the immunisation programs, provides the basis for defining the 56 57 target populations and vaccine characteristics. The output of this work, the first-of-its-kind 58 for leishmaniasis, fills a critical information gap and will provide policy makers and vaccine developers with important insights into the public health relevance of a human leishmaniasis 59 60 vaccine and the strengths of its commercial value proposition. Ultimately this research aims to inform future decisions on disease prioritization and on investments by key stakeholders, 61 as well as to identify areas for further research. 62

# 64 Introduction

Neglected tropical diseases (NTDs) impose a significant health and economic burden on the 65 world's poorest populations and nations [1]. The latest Global Burden of Disease analysis for 66 2019 (GBD 2019) [2] estimates that the 20 NTDs recognised by the World Health 67 Organization (WHO) account for 62.9 million disability-adjusted life years (DALYs) lost and 68 up to 1.25 million deaths annually. A growing number of those NTDs are currently or may 69 soon become vaccine-preventable, including Yellow Fever, Rabies, Ebola, Malaria and 70 Dengue. Yet globally, vaccine development for NTDs progresses at a snail's pace [3], limited 71 by scientific challenges in target antigen identification, the lack of correlates of protection 72 and often unsuitable animal models. In addition, the lack of data on potential market size and 73 74 value creation reduces financial incentives for vaccine developers to invest in those diseases 75 [4].

76

77 In commercial vaccine development efforts, the size of the target population, the revenue potential, the required investment, the clinical development feasibility and the regulatory 78 feasibility are the most influential drivers of decisions [5]. An in-depth understanding of the 79 target populations and of the likely demand are critical inputs for those decisions; this is even 80 more important in the case of NTDs that disproportionally affect low and lower-middle 81 income countries with limited fiscal space. Before proceeding with the clinical development 82 of vaccines for these diseases, commercial developers seek validation of the potential 83 financial return that can be generated by taking them to market. Beyond vaccine developers, 84 policy makers, donors and those responsible for regional health systems also need to take into 85 account the size of the target populations and of the demand for a newly introduced vaccine. 86 This will determine the public health impact in terms of reduction of mortality and morbidity 87 and the financial resources required to implement the vaccination program. In low-and lower-88

middle income countries, those resources may be provided by the public budget or benefit
from direct or indirect donor support (e.g., via Gavi, The Vaccine Alliance (Gavi)).

91

Among the NTDs, leishmaniasis ranks highly in terms of both mortality and morbidity. 92 According to the GBD 2019, between 498,000 and 862,000 new cases of all forms of 93 leishmaniasis are estimated to occur each year [2] resulting in up to 18,700 deaths and up to 94 1.6 million DALYs lost [2]. The leishmaniases are a group of diseases caused by infection 95 with a protozoan parasite of the genus Leishmania (L. Leishmania spp and L. Viannia spp). 96 Visceral leishmaniasis (VL; kala azar) is a systemic disease affecting the internal organs and 97 is usually fatal if untreated [6]. Transmission of VL may be zoonotic (L. infantum) or 98 99 anthroponotic (L. donovani). Although new treatment modalities for VL in South Asia 100 (notably single dose liposomal amphotericin B; AmBisome®) have considerably improved 101 patient experience and outcome, with reported cure rates of up to 95% [7], treatment in other 102 regions remains predominantly based on pentavalent antimonials [8], drugs with a number of severe limitations in convenience and outcome. Post-kala-azar dermal leishmaniasis (PKDL) 103 is a stigmatizing disease that usually follows treatment of VL caused by L. donovani. PDKL 104 patients carry a significant socio-economic and psychosocial burden. In addition, the skin of 105 PKDL patients is a site of parasitism and data derived from xenodiagnosis [9] [10] lends 106 support to the long held view that PKDL patients play a pivotal role in the interepidemic 107 transmission of VL [11] [12]. 108

109

110 Cutaneous leishmaniasis (CL) is the most common form of leishmaniasis affecting humans. 111 This disease is considered to be a zoonosis, with the exception of *L. tropica*, which in certain 112 areas is an anthroponotic disease. Healing of localised CL is usually achieved within 3 to 18 113 months without intervention, though sterile immunity is not thought to be achieved.

Nevertheless, CL carries a significant burden of psychosocial risk that, once accounted for 114 and added to the GBD estimates could lead to estimates of DALYs lost which are up to 10 115 times higher than current figures [13]. Chemotherapeutic options for CL have changed little 116 in over 50 years [14]; those medicines remains expensive and questions are still unanswered 117 about their effectiveness and safety[15]. Once cured, protection against reinfection is 118 believed to be the norm [16] [17] and this supports the argument that vaccine-induced 119 protection should be achievable. Localised lesions can evolve into more severe disease 120 121 characterized by metastasis to mucosal sites (mucocutaneous leishmaniasis; MCL) or the occurrence of multiple (>10) discrete lesions (disseminated cutaneous leishmaniasis; DSL). 122 Rarely, parasites may grow uncontrolled in diffuse lesions across the skin (diffuse cutaneous 123 124 leishmaniasis; DCL).

125

The availability of vaccines against one or more forms of leishmaniasis could provide an 126 127 affordable way to reduce mortality and morbidity, addressing the above-mentioned constraints. Vaccines may be deployed to prevent disease (i.e., prophylactically) or used as 128 alternatives to or in conjunction with existing drugs (i.e., as therapeutic vaccines) for 129 prevention of primary disease or prevention of secondary sequelae. Practical considerations 130 including for example population at risk or alternative treatment options would dictate the 131 relative value or prophylactic vs therapeutic vaccines. While the public health need for a 132 vaccine exists, clinical development efforts have been limited. Numerous vaccine candidates 133 have been evaluated in preclinical models of disease [18] but few have progressed to the 134 clinical trial stage [19]. Currently, only one therapeutic clinical trial is ongoing 135 (Clinicaltrials.gov NCT03969134), and a clinical-grade genetically attenuated live L. major 136 vaccine is due to be manufactured in 2021 [20] to support future trials. Recent progress 137 towards the development of a controlled human challenge model for CL [21] [22] may also 138

139	provide a stimulus for the clinical development of other candidate vaccines. However, the
140	absence of a consensus on the size of the target populations, the paucity of data to support an
141	indication for use in each disease state and the lack of realistic demand scenarios are likely
142	determinants of the scarce interest from the pharmaceutical industry and philanthropic
143	donors. Estimates of the total burden of leishmaniases have been difficult due to the
144	prevailing poor knowledge of the geographical distribution of the diseases. A further
145	difficulty in burden estimation is the epidemic nature of the disease, leading to significant
146	interannual variation in disease burden [23]. Those factors have made the definition of a
147	reliable demand forecast for a leishmaniasis vaccine very challenging.
148	
149	To address this critical gap, we developed a first in-depth demand forecast for a leishmaniasis
150	vaccine that indicates that prophylactic vaccines for visceral and cutaneous leishmaniasis
151	could have not only a solid public health value proposition but also, subject to countries
152	confirming their interest for the vaccine and willingness to pay, a commercial potential that
153	can attract the interest of vaccine developers and manufacturers.
154	
155	Methods
156	To develop the leishmaniasis vaccine demand forecast we employed established population-
157	based forecasting methods [24] [25] [26]. We started from the definition and estimate of the
158	target populations for a leishmaniasis vaccine based on the use cases for such vaccine, and
159	the evolving epidemiology of the disease. We then simulated the potential reached
160	populations by assessing and by defining a set of assumptions on the sequence of adoption of

160 populations by assessing and by defining a set of assumptions on the sequence of adoption of

the vaccine in endemic countries and the impact of the introduction of the vaccine on those

162 populations. Finally, we developed the demand forecast by translating these data into doses

161

163 of vaccine required, taking into account vaccine characteristics, immunisation schedule and

specific programmatic issues. The logical framework of the methodology is represented inFigure 1.

166

#### 167 Use cases definition

168 To identify the main use cases, defined as "the specific situation(s) in which a product or a

service could potentially be used to accomplish a defined goal", a workshop was held

170 bringing together researchers involved in the development of leishmaniasis vaccines and

171 therapies, public health professionals and other key opinion leaders<sup>2</sup>. The clinical

172 manifestations of the disease and the treatment goals, differentiated by prophylaxis (primary

173 prevention), prevention of the development of PKDL and treatment of VL, CL or PKDL

174 (therapeutic), were identified as key determinants of the use cases for a leishmaniasis

vaccine. Consensus emerged on the factors most likely to require and / or trigger alternative

approaches and distinct pathways to disease control. Vector species and subspecies as well as

177 geography were deemed potentially relevant dimensions in future refinement of the use cases.

178

### 179 Estimating the target populations

180 The target populations for the prevention of VL and CL were defined as the populations at 181 risk of these diseases . For the prevention of VL (PKDL) and the treatment of PKDL, the 182 target population was defined based on VL incidence and PKDL prevalence, respectively. 183 Data for these populations are limited and often inconsistent in terms of geographical and

<sup>&</sup>lt;sup>1</sup> The concept of use case was originally developed in software and systems engineering, to describe a list of actions or steps defining the interactions between an actor and a system to achieve a goal.

<sup>&</sup>lt;sup>2</sup> The workshop took place in May 2019 at the Wellcome Trust in London with the participation of: Jorge Alvar (DNDi), Simon Croft (LSHTM), Tom Evans (Vaccitec), Nirmal Kumar Ganguly (ICMR), Birgitte Giersing (WHO), Bethan Hughes (Wellcome Trust), Christiane Juhls (Mologen), Paul Kaye (Univ. of York), Greg Matlashewski (McGill), Ahmed Musa (Sudan MOH), Richard Muscat (Wellcome Trust), Steve Reed (IDRI).

temporal coverage. Therefore, estimates were defined through an iterative process that started
with the identification of the geographies at risk (whether entire countries or specific regions)
followed by the collection of the available global, national and regional data. Estimates
resulting from different sources were further scrutinized and used to define an estimate with
upper and lower range limits to serve as a "base" case.

189

Population at risk for VL. 25 higher-risk countries are classified by the WHO as "high burden 190 191 countries" or those with incidence above 10/10,000 according to latest estimates from the GBD of 2019 [2] (see Supplementary Text). A lower national inclusion threshold was used 192 compared to the 1/10,000 indicated as the national target for the elimination of leishmaniasis 193 194 as a public health problem, to reflect the heterogenous disease occurrence within each 195 country and the fact that reducing incidence to the target in the risk areas will result in a subsequent reduction to even lower level of the national incidence [27]. We assumed that in 196 197 those 25 countries VL burden supports the rationale for vaccine use. At-risk population data were retrieved at country level, where available, or at regional or global level [28][29][30]. 198 For each of those countries, only the portion of the population considered living in at-risk 199 areas was included as target for the vaccination program. The upper limit of the size of the at-200 risk population was defined based on data from 13 WHO leishmaniasis country profiles [31] 201 202 (data from 2014, 15 and 16 depending on the country) integrated with data from Pigott et al [28] that includes all geographical areas (at national or sub-national level) which could 203 become endemic in the future. Additional validations were performed for the total population 204 205 of the Indian subcontinent (India, Bangladesh and Nepal) [32]. The consolidated estimate for the 25 countries was allocated to the year 2014. The base case was centred around the latest 206 available global WHO estimates of the overall population at risk of all leishmaniases (for 207 2010) under the assumption that 100% of that population is at risk of VL. The assumption is 208

209	consistent with the analysis by Pigott et al [28] where the difference in size of VL and CL at-
210	risk populations was minimal. The lower limit of the range was based on the 2009 global
211	estimates developed by DNDi [30]. Since the year of reference was different for the different
212	data sources, projections up to 2018 were built for each dataset, applying a population growth
213	rate of 1.83%, corresponding to the 2010-2015 regional growths as reported by UN/DESA
214	[33] and weighted based on regional VL cases from the GBD estimates 2019 for Asia
215	inclusive of the Middle East, Africa and Latin America.
216	
217	VL incidence. Information for the 9 VL endemic countries relevant for PKDL was retrieved
218	from the latest GBD 2019 [2] for the period 2010-2019. Other estimates of new VL cases
219	were sourced from Alvar (personal communication) for India and East Africa for 2018 and
220	from Mondal et al. [34] for India for the period 2005-2008.
221	
222	PKDL prevalence. Estimates of the rate of occurrence of sequelae of VL cases were used to
223	define PKDL incidence. Different regional estimates were used for Asia [35] and Africa with

high, low and medium points being defined. From the PKDL incidence, the 2016 PKDL

estimated prevalence was derived considering an average 3.5 years duration of the lesions asindicated by Mondal [34].

227

*Population at risk for CL*. 34 high-risk countries were selected, either those identified by
WHO as high burden countries or those with an incidence above 5/100,000 according to the
latest GBD estimates for 2019 [2]. For India, only 2 states with high endemicity (Rajasthan
[36] and Kerala [37]) were included. Similar to VL, these countries and states were assumed
to be those where CL burden supports the rationale for vaccine introduction. For each of
those countries, only the portion of the population living in at-risk areas was included as a

target for the vaccination program. The upper limit of the size of the at-risk population was 234 defined based on data from 12 WHO leishmaniasis country profiles [31] (data from 2014, 15 235 236 and 16 depending on the country) and the consolidated regional 2014 estimate for the 12 countries in the American region [38], integrated with data from Pigott et al. [28] from 2014. 237 The consolidated estimate for the 34 countries was centred on the year 2014. The mid-point 238 of the range was based on the global estimates from DNDi of the total cases of leishmaniasis 239 [39], under the assumption that the countries included in the estimate were all at risk for CL. 240 The lower limit of the range was based on the global WHO estimates for 2010 [29] of the 241 overall population at risk of all leishmaniases under the assumption that 100% of these 242 populations are at risk of CL. Similar to VL, projections up to 2018 were built applying a 243 244 1.43% population growth rate for the period 2010-2015. This rate corresponds to the regional 245 estimates as reported by UN/DESA[33] weighted based on the latest available regional CL cases from GBD 2019 for Asia inclusive of Middle-East, Africa and Latin America. 246 247

The four estimates above were then projected through the year 2040 by using the weighted 248 regional population growth rate (based on regional shares of the respective disease for the 249 period 2019-2040 as estimated by the UN DESA[33]. Specifically, a growth rate of 1.80% 250 was used for the population at risk of VL and 1.42% for the population at risk of CL. For the 251 projection of the VL cases, a wave-shaped incidence curve was applied for the period 2017-252 2040 reflecting an epidemiological trend with 5 years of decline followed by 5 years of 253 growth, but less accentuated than the cyclical incidence variations induced by El Niño [40] 254 [41] [42], and using the UN DESA regional average annual growth rates for the period 2010-255 2016 (with a positive sign in the growth and a negative sign in the decline years). 256

257

### 258 Modelling the targeted population

Adoption sequence in the targeted countries. The adoption curve indicates the growing 259 proportion of the targeted population that can be reached with the vaccine as result of country 260 261 introduction decisions. Country adoption decisions are often guided by an assessment of the benefits of vaccination under different conditions by the National Immunisation Technical 262 Advisory Group (NITAG) based on the country and region-specific context. The likelihood 263 of NITAG recommendations for vaccine introduction in different countries was accounted for 264 by including only high-risk countries based on incidence thresholds as indicated earlier. 265 In contrast to prophylactic vaccines, preventative and therapeutic vaccines do not have the 266 same requirement for centralized decision-making. The countries where PKDL is endemic 267 are thus assumed as introducing the vaccine. 268

269

In view of the early state of development, interest of individual countries for introduction of a leishmaniasis vaccines cannot easily be assessed, hence a proxy was identified to define the sequence of adoption in the selected countries. Since 21 of the 25 countries (84%) which are likely targets for the introduction of a VL vaccine and 13 of the 34 countries (38%) which are likely targets for a CL vaccine are or were eligible for Gavi support, the sequence of introduction in the Gavi countries for Pneumococcal Conjugate Vaccine [43] was selected as the most meaningful proxy.

277

Impact of vaccine introduction on target populations. The introduction of a leishmaniasis
vaccine that triggers an effective host protective immune response will decrease the size of
the population at risk. We assumed that the introduction of a VL prophylactic vaccine would
decrease populations at risk and also reduce transmission in areas with exclusive
anthroponotic transmission (South Sudan, Sudan, Somalia, India, Nepal, Bangladesh and the
Xinjiang region in China). In those countries, it was assumed that the decline of the

population at risk would take place linearly and that immunisation would progressively be 284 stopped once all blocks or districts have reached a VL elimination target of less than 1 VL 285 286 case per 10,000 per year. This is estimated starting from the sixth year after vaccine introduction, spreading over a period 4 years. In areas where VL transmission is zoonotic, 287 vaccination is assumed to continue unchanged. In a similar fashion, we assumed that a CL 288 prophylactic vaccine, while protecting individuals, will have less impact on transmission 289 given the zoonotic nature of this disease, hence immunization will not be stopped in any CL 290 at-risk area. Finally, the impact of a VL prophylactic vaccine on VL incidence and thus, 291 indirectly, also on the size of the target population for the prevention of PKDL was estimated 292 referring to recent disease transmission modelling work for India, where anthroponotic 293 294 transmission was assumed [44] (29). In that model (under the assumption that asymptomatic 295 individuals also contribute to VL transmission), the reduction in the number of cases following prophylactic vaccination with a 50% efficacious vaccine covering 100% of the 296 297 population was estimated to be 30%, 50% and 62% in years 1, 2 and 3 following the introduction of the vaccine [44]. 298

299

The impact of a PKDL preventative vaccine on PKDL incidence was modeled taking into account the following factors: i) the year of introduction of the vaccine, ii) the proportion of the total population reached as a result of a vaccine deployment spread out over 2 years, and iii) the estimated reduction of VL cases. As a result, a 50% reduction in year 2 and a 90% reduction from year 3 onward is used to estimate the reduction in the number of cases in each of the 3 scenarios with year 1 being the year of introduction of the vaccine.

306

For the impact of a PKDL therapeutic vaccine on PKDL incidence, no changes to the targetpopulation were assumed.

309

#### **310** Modelling the demand for a leishmaniasis vaccine

311 With the target population estimates established and expected changes to the size of those

- 312 populations modelled, we subsequently defined a number of assumptions related to the
- 313 vaccination program and to the vaccine characteristics.

314

Date of registration of the vaccine. Based on the current status of vaccines in clinical 315 development, we took the earliest year of first registration for both VL and CL preventative 316 vaccines as 2029. We then assumed 12 months for obtaining WHO prequalification (PQ) to 317 allow procurement through the United Nations system. The PQ date is based on the 318 319 assumption that the vaccine will be developed by an experienced manufacturer and is 320 consistent with assumptions used by the WHO in similar analyses [45]. Thus, 2030 was assumed as the year of start of a phased global roll-out for both indications. A PKDL 321 322 therapeutic vaccine (ChAd63-KH) is in Phase IIb therapeutic trial in in Sudan [46] while Phase II trials of the same vaccine to prevent PKDL in previously treated VL patients may 323 begin in 2021. Should one or both of these approaches prove successful, such a vaccine might 324 progress through other trials to allow registration in 2027. 325

326

*Vaccine characteristics and immunisation schedule:* For estimating the demand, key vaccine product characteristics were assumed. Target product profile (TPP) assumptions relevant to the calculation of a demand forecast are shown in **Table 4**. Of special importance is the assumption of cross-protection of a vaccine against visceral and cutaneous leishmaniasis, as suggested by studies with different *Leishmania* species in experimental models [47] [48]. Assumptions regarding the duration of protection and number of vaccination series (the number of times a person undergoes one full vaccination cycle) were made based on historic

evidence, regulatory assumptions and practical considerations. A minimum of five years 334 duration of protection was assumed based on the consideration that a shorter duration would 335 336 likely render the vaccine too cumbersome for implementation and too expensive for use in view of the number of doses required to maintain protection for the first 15 years of life (e.g., 337 the age groups with the highest disease burden). In addition, key assumptions were made 338 regarding the immunisation schedule, including broad age-range catch-up campaigns at start 339 of the vaccine roll-out in each country with the goal of reducing susceptible unprotected 340 populations in an efficient and timely manner. To capture a main area of uncertainty, a 341 second more conservative scenario has been run simulating a first priming dose followed by 342 1 booster dose after 5 years and a second booster after 10 years for a total of 3 doses (instead 343 344 of the 6 of the base case). 345 Vaccine coverage. The maximum achievable coverage was estimated for different vaccine 346 347 schedules based on coverage achieved in routine vaccination in the same age groups [49] [50] or coverage achieved in campaigns in the relevant regions [51](Table 5). 348 As a simplifying assumption, the time required to achieve the full coverage within each 349 country was set at 12 months. 350 351 352 A detailed review of the calculations is available in **Supplementary Text File**. 353 354 Results **Determination of use cases** 355 Eleven use cases emerged as a result of the review (Table 1). Three of these use cases were 356 357 deprioritised in view of their limited size and impact on the total demand. For each of the remaining eight use cases, the most appropriate delivery strategy was defined according to 358

the target geography and goal (prophylaxis, prevention or treatment). Due to the focal 359 distribution of leishmaniasis and the high population mobility in most of the endemic areas, 360 delivery strategies were assumed to focus on at-risk populations rather than at-risk areas. In 361 finalising the use cases, the following two aspects were also considered: (a) a CL therapeutic 362 vaccine will target a subset of the population also targeted by the CL prophylactic vaccine 363 (the population at risk of CL); (b) vaccine development efforts will most likely not focus on 364 geographically limited indications. As result of those considerations, the eight prioritised use 365 cases were further consolidated into four by eliminating the differentiation by geography and 366 co-morbidity for the CL use cases (Table 2). These four use cases and the related delivery 367 strategies provide the foundation for the assessment of the size of the demand for 368 369 leishmaniasis vaccines given the different indications.

370

#### **371 Target population estimates**

372 Using a variety of source data (see Methods), we generated upper and lower limits of target populations that are at risk of developing VL or CL and who might therefore benefit from a 373 prophylactic vaccine. Similarly, upper and lower limits are estimated for preventative and 374 therapeutic vaccines for PKDL. In addition, we identified a base case or central-point 375 estimate of the population at risk (Table 3). For both VL and CL prevention, the 2018 376 estimates of populations at risk ranged from 647 million to 235 million for VL and from 1 377 billion to 392 million for CL. Based on the assumption of cross-protectivity and taking into 378 account the population of the 4 countries<sup>3</sup> included in the analysis that are endemic for both 379 manifestation of the disease, approximately 29% of the population at risk of CL is considered 380 also at risk of VL and was therefore deducted from the calculation of the CL target 381

<sup>&</sup>lt;sup>3</sup> Brazil, India, Paraguay and Sudan

population. Estimates for the prevention of PKDL ranged from 31,892 to 12,635 and for
treatment of PKDL from 6,141 to 2,460, emphasizing a marked difference in scale for these
different indications.

385

# **386** Potential demand estimates for VL and CL prophylactic vaccines.

Based on the above assumptions, we calculate that peak combined potential demand for VL 387 and CL would be approximately 190 million doses in 2033 (of which approximately 1/3 are 388 389 for VL) (Figure 2). Demand shows a variable profile as a result of the impact of the large catch-up campaigns aimed at multiple age cohorts (10 cohorts for VL and 25 cohorts for CL): 390 as the population covered by the initial catch-up campaigns grows older, the portion of the 0-391 392 15 age group requiring boosting via routine immunization will grow. After 2034, the 393 increasing impact of the vaccine will result in the progressive reduction in size of the VL atrisk population offsetting the additional populations introducing the vaccine. As a 394 consequence, demand is predicted to decline progressively until 2038, reflecting the 395 elimination [52] of VL in the Indian subcontinent<sup>4</sup>, and thereafter to stabilise at around 160 396 million doses per year across the two indications. 397 398

Estimates in single years are a function of many variables and may have limited predictive value and the portion of demand that will be served would most likely be capped at some level due to limits of manufacturing capacity. The cumulative number of doses over the 11 years between 2030 and 2040 is thought to provide a reasonable and relevant estimate resulting in a demand for approximately 1.6 billion doses across the 2 disease states

<sup>&</sup>lt;sup>4</sup> Such an assumption, based on the historical trend of the last decade requires continued investment in surveillance and introduction of better diagnostic methods [62]

(approximately 500 million for VL and 1.1 billion for CL) or an average of 145 million doses
per year. It is important to note that this estimate is significantly impacted by the assumption
that six doses will be required for each person vaccinated. In the more conservative scenario
where only 3 doses are required, those numbers are reduced by half (800 million doses over
the 11 years across the 2 disease states).

409

Of interest is the split between campaigns (for catch-up vaccination at start) and routine use, 410 with the former being more volatile and dependent on the number of cohorts targeted and the 411 timing of catch-up campaigns in different countries. It is estimated that 39% of the doses 412 (approximately 615 million doses) will be used in campaigns to reach 5-14 year olds for 413 414 protection against VL and 5-29 year olds for protection against CL in view of the different 415 age distribution of the disease [53] while the remaining 61% (approximately 980 million doses) will be used in routine immunisation in areas with high CL prevalence (because of the 416 larger and stable population reached) (Figure 3). 417

418

Two additional simulations were also performed. One simulation used the lower population 419 scenario as a way of reflecting a conservative block-focused immunization strategy and a 420 significant negative impact of vaccine hesitancy. A second simulation used the higher 421 422 population scenario so as to capture a more extensive definition of risk-areas and also incorporating a broader impact of climate change on the spread of the disease. The first 423 scenario was reflected in a reduction of the total doses over the 11 years from 1.6 billion to 424 858 million (301 million for VL and 557 million for CL); the second scenario resulted instead 425 in an increase to 2.2 billion doses over the 11 years (830 million for VL and 1.4 billion for 426 CL). 427

428

# 429 Potential demand estimates for PKDL targeted vaccines.

Assuming implementation of an effective VL prophylactic vaccine, total PKDL demand will 430 peak at 27,300 doses in 2028 with approximately 90% of demand for preventive use (Figure 431 4). For therapeutic use, demand is estimated at 3300 doses in 2027 (at the time of vaccine 432 introduction) declining to less than one hundred doses by 2036. Overall demand will further 433 decline to less than 1,000 doses in 2039 as result of the cumulative impact of preventative 434 vaccine use, compounded by the reduction in VL cases driven by the introduction of the VL 435 prophylactic indication. The total demand for a PKDL therapeutic vaccine over the 13 years 436 will be 7,200 doses, while the total demand for a vaccine to prevent PKDL over the same 437 period will be 161,000 doses. Of interest is the scenario where a stand-alone therapeutic / 438 439 preventative vaccine for PKDL is developed in the absence of an effective prophylactic 440 vaccine for VL and hence with no vaccine-related reduction in VL cases. Under those circumstances, the total potential demand for a PKDL vaccine doubles to more than 330,000 441

442 doses over the period.

443

# 444 Discussion

In order to fully ascertain the potential interest of developers for a program aimed at
developing a vaccine against leishmaniasis, we conducted an in-depth analysis of the
potential global demand for leishmaniasis vaccines that is generally agnostic to the nature of
the vaccine.

449

450 The assessment of the use cases for leishmaniasis vaccines emphasizes four main indications:

451 two for the prevention of VL and CL respectively, and two for the prevention and treatment

452 of PKDL. In endemic countries, those vaccines will reduce cases of disease and decrease

453 community transmission. Based on the estimates of the populations at risk and the

454 consequent demand, prophylactic VL and CL vaccine indications are the most attractive
455 scenarios both from a public health and commercial standpoint. A vaccine that is cross456 protective against VL and CL has the strongest value proposition, whilst only one indication
457 still allows for a significant demand size and public health impact. PKDL indications also
458 retain their importance from a public health standpoint or in view of existing progress in
459 clinical development that may lead to the earlier availability of this vaccine.

460

Availability of a vaccine for one or more of these indications will provide an opportunity to 461 reduce the threat of leishmaniasis as a public health problem in 57 countries<sup>5</sup>. This includes 462 22 countries in the African continent, 14 in the Americas, 19 in Asia, and 2 in the European 463 region. At the same time 3 of these countries are High-Income (HICs), 18 Upper Middle-464 income (UMICs), 19 Lower-Middle-Income (LMICs) and 15 Low-income (LICs) [54] as 465 defined by the World Bank income classification. Of the latter two groups, 22 countries are, 466 and 10 have previously been, eligible for Gavi support including funding for vaccine 467 procurement. It is assumed that HICs or UMICs would potentially be able to self-finance, 468 while LMICs and LICs could benefit from the financial support of Gavi and other donors. 469 470 The total population potentially targeted by leishmaniasis vaccines approximates 1.1 billion 471 in 2030 by the time of introduction of the vaccine. On the basis of data from 2018, the 472 population at risk of VL (404 million with a range between 235 and 646 million) and at risk 473 of CL (765 million with a range between 392 million and 1 billion) represents the near 474 totality of the potential target for the vaccine while the numbers of VL cases in the targeted 475 countries (16,129 new cases per year for 2030 with a range between 2,843 and 25,068 cases) 476

<sup>&</sup>lt;sup>5</sup> The 57 countries are split as follow: India and Sudan, for the 3 manifestations of the disease, 4 countries for VL and CL, 7 countries for VL and PKDL, 14 countries for VL only, and 30 countries for CL only

477	and of PKDL (3,104 new cases per year for 2030 in absence of a vaccine, with a range
478	between 600 and 4,752 cases) are much more limited. It is evident that vaccine use in such
479	large populations could result in significant public health benefits.
480	
481	The vaccine supply required over 10 years (2030-2040) for the implementation of

immunisation programs against VL or CL could be substantial: approximately 1.1 billion 482 doses of vaccine against CL (range: 0.5 - 1.4 billion doses) and 0.5 billion doses of vaccine 483 against VL (range:  $\sim 0.3 - 0.8$  billion doses). Markets of this size have the potential to attract 484 the interest of vaccine manufacturers, even more so in view of the mix of economies 485 involved, some of which may self-finance a respective immunization program. For this 486 487 interest to materialise, utmost transparency will be necessary on the countries' willingness 488 and ability to pay for the vaccines, as well as clarity on WHO recommendations for vaccine use. Establishment of incentive mechanisms, such as Advanced Market Commitments [55] 489 490 and Priority Review Vouchers [56], can also play an important incentivizing role. This will be critical for supporting the progress of current vaccine development efforts. 491

492

It is not yet established whether a vaccine that prevents clinical VL will also prevent the 493 development of PKDL. If this were not the case, making available a vaccine that is selective 494 for PKDL may be more challenging in view of the more limited potential demand. However, 495 a different approach may be pursued for this indication leveraging the limited demand as an 496 opportunity instead of a constraint. Regulatory frameworks for orphan or compassionate use 497 indications could be exploited and combined with limited manufacturing needs and 498 investments, reducing greatly the cost and the risk for a manufacturer. Such a focused 499 approach to vaccine financing should be explored to address the burden of PKDL. 500

501

To support countries in their assessment of the public health impact of a leishmaniasis 502 vaccine and prospective manufacturers of the commercial value proposition of those 503 504 vaccines, clarity on target populations and demand is paramount. The Hib Initiative, as well as the Pneumococcal and Rotavirus Vaccine Accelerated Development and Introduction 505 Plans (PneumoADIP and RotaADIP) provide examples on how a concurrent effort on data 506 generation, clinical development and public advocacy was able to raise awareness on diseases 507 with a heavy burden on populations of LMICs and LICs [57]. Such an approach is even more 508 509 critical for neglected tropical diseases such as leishmaniasis.

510

The limitations of this analysis, as for any forecasting exercise, relate to various elements of 511 512 uncertainty. Firstly, the forecast is dependent on the estimates of the at-risk populations in 513 endemic or potentially endemic areas as well as on the assumed future incidence and prevalence of the disease. With current leishmaniasis control programmes in place in certain 514 515 parts of the world, such incidence will depend on the success of these programmes. There is no clear consensus among experts and estimates show a high degree of variability while an 516 agreed definition of the target population at risk, by countries or sub populations of countries, 517 is missing. Secondly, assumptions concerning the probability of country vaccine introduction 518 are subject to a high degree of uncertainty given that vaccines will likely not be available for 519 another decade. Thirdly, the estimate of the impact of the use of vaccines in the target 520 populations is based on a set of assumptions while awaiting the outcomes of vaccine trials 521 Work done by Erasmus MC (University Medical Center, Rotterdam) provides information on 522 the potential impact of various VL vaccines on VL incidence in an Indian setting [44], but not 523 elsewhere. Whilst our modelling assumptions include transmission by asymptomatic cases of 524 VL, a recent study from India suggests that this may be more limited than previously thought 525 [58]. Studies of transmission competence across the disease spectrum in other regions where 526

VL is endemic are clearly warranted. Additional simulations of the impact of vaccines in CL 527 and VL populations at risk (including the likelihood of interruption of transmission and of the 528 impact of a VL prophylactic vaccine), will further improve our understanding of population 529 dynamics and vaccine effectiveness. Finally, a number of initial assumptions were made on 530 variables such as the sequence of country introduction, vaccine uptake, achievable and 531 desired coverage and vaccination schedules. Changes in these parameters and the priority 532 countries introducing the vaccines will impact the forecasted demand. As an example, the 533 534 impact of a different immunisation schedule, as captured in the conservative scenario described in the results section (with a reduced series of 3 doses instead of 6), has the 535 potential to reduce demand by up to 50%. Getting closer to registration, more precise 536 537 information about vaccine product characteristics, and the likely program designs and 538 country interest will allow for more refined estimates.

539

540 In conclusion, there is a growing consensus on the need for a vaccine against leishmaniasis to achieve a reduction of the burden of disease [59][60][61]. Clarity about the prospective size 541 of the vaccine demand in terms of target population and number of doses required is crucial 542 to inform decisions of manufacturers, donors and countries. Our first-of-a-kind analysis 543 provides a global estimate of the potential demand for leishmaniasis vaccines across a set of 544 different indications. Subject to prioritization of country and global decision makers, a 545 leishmaniasis vaccine with a VL and/or CL indication could not only provide a significant 546 contribution to the reduction of the burden of NTDs but also has the potential of being an 547 interesting commercial prospect for vaccine developers. Further analyses to confirm the 548 likelihood and strength of interest of country decision makers in prioritising leishmaniasis 549 vaccines in their adoption decisions are warranted. This will enable further clarification on 550 the potential reduction in the burden of the disease and cost-effectiveness of these vaccines. 551

Е	с	2
Э	Э	2

553

# 554 Acknowledgments

The authors of this article wish to thank the members of the expert group who provided insights and guidance in the development of the use cases and who critically reviewed the manuscript. In particular, we thank Jorge Alvar, Simon Croft, Nirmal Kumar Ganguly and Greg Matlashewski who dedicated time to validate some of our assumptions. Finally, we are grateful to the Wellcome Trust for supporting expert meetings during the project timeline and allowing for additional fruitful interactions.

561

### 562 Funding

563 This work was funded by a Translation Award from the Wellcome Trust (Grant No. 108518;

to PMK). The funder had no role in the design or execution of the study or the decision to

565 publish. EALR gratefully acknowledges funding of the NTD Modelling Consortium by the

566 Bill and Melinda Gates Foundation (OPP1184344).

567

#### 568 **Conflict of interest statement**

PMK is co-author of a patent protecting the gene insert used in *Leishmania* candidate vaccine
ChAd63-KH (Europe 10719953.1; India 315101) and is funded by the UK Medical Research
Council / Department for International Development to develop a controlled human infection
model for sand fly-transmitted cutaneous leishmaniasis. MMGH Consulting were appointed
to lead the work under contract from the University of York.

574

#### References 576 Hotez PJ. The global fight to develop antipoverty vaccines in the anti-vaccine era. 577 1. Hum Vaccines Immunother. 2018;14: 2128-2131. 578 579 doi:10.1080/21645515.2018.1430542 Abbafati C, Machado DB, Cislaghi B, Salman OM, Karanikolos M, McKee M, et al. 2. 580 Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: 581 a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396: 582 1204-1222. doi:10.1016/S0140-6736(20)30925-9 583 3. Kaslow DC, Black S, Bloom DE, Datla M, Salisbury D, Rappuoli R. Vaccine 584 candidates for poor nations are going to waste. Nature. 2018. doi:10.1038/d41586-018-585 07758-3 586 587 4. Bottazzi ME, Hotez PJ. "Running the Gauntlet": Formidable challenges in advancing neglected tropical diseases vaccines from development through licensure, and a "Call 588 to Action." Hum Vaccines Immunother. 2019;15: 2235–2242. 589 doi:10.1080/21645515.2019.1629254 590 MMGH. Effective Vaccine Ecosystem, - a reaserch project for the Wellcome Trust. 591 5. 2020. 592

- World Health Organization. Key Facts Leishmaniasis. In: WHO Website [Internet].
   2020 [cited 20 Feb 2020]. Available: https://www.who.int/news-room/fact-
- 595 sheets/detail/leishmaniasis
- 596 7. Chakravarty J, Sundar S. Current and emerging medications for the treatment of597 leishmaniasis. Expert Opinion on Pharmacotherapy. 2019.
- doi:10.1080/14656566.2019.1609940
- 599 8. Alves F, Bilbe G, Blesson S, Goyal V, Monnerat S, Mowbray C, et al. Recent
- 600 development of visceral leishmaniasis treatments: Successes, pitfalls, and perspectives.

601 Clinical Microbiology Reviews. 2018. doi:10.1128/cmr.00048-18

- 602 9. Molina R, Ghosh D, Carrillo E, Monnerat S, Bern C, Mondal Di, et al. Infectivity of
- 603 Post-Kala-azar Dermal Leishmaniasis Patients to Sand Flies: Revisiting a Proof of
- 604 Concept in the Context of the Kala-azar Elimination Program in the Indian
- 605 Subcontinent. Clin Infect Dis. 2017;65: 150–153. doi:10.1093/cid/cix245
- 10. Singh OP, Tiwary P, Kushwaha AK, Singh SK, Singh DK, Lawyer P, et al.
- 607 Xenodiagnosis to evaluate the infectiousness of humans to sandflies in an area
- 608 endemic for visceral leishmaniasis in Bihar, India: a transmission-dynamics study. The

609		Lancet Microbe. 2021. doi:10.1016/s2666-5247(20)30166-x
610	11.	Mukhopadhyay D, Dalton JE, Kaye PM, Chatterjee M. Post kala-azar dermal
611		leishmaniasis: An unresolved mystery. Trends Parasitol. 2014;30: 65–74.
612		doi:10.1016/j.pt.2013.12.004
613	12.	Le Rutte EA, Zijlstra EE, de Vlas SJ. Post-Kala-Azar Dermal Leishmaniasis as a
614		Reservoir for Visceral Leishmaniasis Transmission. Trends in Parasitology. 2019.
615		doi:10.1016/j.pt.2019.06.007
616	13.	Bailey F, Mondragon-Shem K, Hotez P, Ruiz-Postigo JA, Al-Salem W, Acosta-
617		Serrano Á, et al. A new perspective on cutaneous leishmaniasis—Implications for
618		global prevalence and burden of disease estimates. PLoS Negl Trop Dis. 2017;11: 2-6.
619		doi:10.1371/journal.pntd.0005739
620	14.	Nassif PW, De Mello TFP, Navasconi TR, Mota CA, Demarchi IG, Aristides SMA, et
621		al. Safety and efficacy of current alternatives in the topical treatment of cutaneous
622		leishmaniasis: A systematic review. Parasitology. 2017;144: 995–1004.
623		doi:10.1017/S0031182017000385
624	15.	Pinart M, Jr R, Gas R, Ce P, An SM, Reveiz L, et al. Pinart M, Rueda JR, Romero
625		GAS, Pinzón-Flórez CE, Osorio-Arango K, Silveira Maia-Elkhoury AN, Reveiz L,
626		Elias VM, Tweed JA. 2020.
627		doi:10.1002/14651858.CD004834.pub3.www.cochranelibrary.com
628	16.	Melby PC. Experimental Leishmaniasis in Humans: Review. Rev Infect Dis. 1991;13:
629		1009–1017. doi:10.1093/clinids/13.5.1009
630	17.	Scott P, Novais FO. Cutaneous leishmaniasis: Immune responses in protection and
631		pathogenesis. Nature Reviews Immunology. 2016. doi:10.1038/nri.2016.72
632	18.	Cecílio P, Oliveira F, Silva AC da. Vaccines for Human Leishmaniasis: Where Do We
633		Stand and What Is Still Missing? Leishmaniases as Re-emerging Diseases. InTech;
634		2018. pp. 59-79. doi:10.5772/intechopen.75000
635	19.	Moafi M, Sherkat R, Taleban R, Rezvan H. Leishmania vaccines entered in clinical
636		trials: A review of literature. International Journal of Preventive Medicine. 2019.
637		doi:10.4103/ijpvm.IJPVM_116_18
638	20.	Zhang WW, Karmakar S, Gannavaram S, Dey R, Lypaczewski P, Ismail N, et al. A
639		second generation leishmanization vaccine with a markerless attenuated Leishmania
640		major strain using CRISPR gene editing. Nat Commun. 2020;11: 1-14.
641		doi:10.1038/s41467-020-17154-z

642	21.	Srivastava S, Shankar P, Mishra J, Singh S. Possibilities and challenges for developing
643		a successful vaccine for leishmaniasis. Parasites and Vectors. 2016;9: 1-15.
644		doi:10.1186/s13071-016-1553-y
645	22.	Ashwin H, Sadlova J, Vojtkova B, Becvar T, Lypaczewski P, Schwartz E, et al.
646		Characterization of a new Leishmania major strain for use in a controlled human
647		infection model. Nat Commun. 2021. doi:10.1038/s41467-020-20569-3
648	23.	Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis
649		worldwide and global estimates of its incidence. PLoS One. 2012;7.
650		doi:10.1371/journal.pone.0035671
651	24.	Zuber PLF, Dumolard L, Shirey M, Rizzo I, Marshall J. Forecasting demand for Hib-
652		containing vaccine in the world's poorest countries: A 4-year prospective experience.
653		Vaccine. 2009;27: 410-415. doi:10.1016/j.vaccine.2008.10.069
654	25.	Amarasinghe A, Wichmann O, Margolis HS, Mahoney RT. Forecasting dengue
655		vaccine demand in disease endemic and non-endemic countries. Hum Vaccin. 2010;6:
656		745–753. doi:10.4161/hv.6.9.12587
657	26.	Cernuschi T, Malvolti S, Nickels E, Friede M. Bacillus Calmette-Guérin (BCG)
658		vaccine: A global assessment of demand and supply balance. Vaccine. 2018;36.
659		doi:10.1016/j.vaccine.2017.12.010
660	27.	Jervis S, Chapman LAC, Dwivedi S, Karthick M, Das A, Le Rutte EA, et al.
661		Variations in visceral leishmaniasis burden, mortality and the pathway to care within
662		Bihar, India. Parasit Vectors. 2017. doi:10.1186/s13071-017-2530-9
663	28.	Pigott DM, Sumiko Mekaru HR, Gething PW, George DB, Myers MF, Reithinger R,
664		et al. Global Distribution Maps of the Leishmaniases. Elife. 2014;2010: 1–21.
665		doi:10.7554/eLife.02851
666	29.	World Health Organization. Control of the leishmaniases. World Health Organ Tech
667		Rep Ser. 2010; 22–26.
668	30.	Drug for Neglected Disease Initiative. DNDi - NewsLetter. [cited 2 Jan 2020].
669		Available: https://www.dndi.org/newsletters/n18/4_1.php
670	31.	World Health Organization. WHO   New leishmaniasis country profiles based on
671		routine surveillance data. [cited 2 Jan 2020]. Available:
672		https://www.who.int/neglected_diseases/news/New_leishmaniasis_country_profiles_b
673		ased_on_routine_surveillanc/en/
674	32.	Karunaweera ND, Ferreira MU. Leishmaniasis: Current challenges and prospects for

elimination with special focus on the South Asian region. Parasitology. 2018;145: 675 425-429. doi:10.1017/S0031182018000471 676 33. United Nations - Department for Economic and Social Affairs. World Population 677 Prospects - Population Division - United Nations. In: World Population Prospects 678 2019 [Internet]. [cited 2 Jan 2020]. Available: 679 https://population.un.org/wpp/Download/Standard/Population/ 680 34. Mondal D, Bern C, Ghosh D, Rashid M, Molina R, Chowdhury R, et al. Quantifying 681 the infectiousness of post-kala-azar dermal leishmaniasis toward sand flies. Clin Infect 682 Dis. 2019;69: 251-258. doi:10.1093/cid/ciy891 683 35. Zijlstra EE, Alves F, Rijal S, Arana B, Alvar J. Post-kala-azar dermal leishmaniasis in 684 the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination 685 686 Programme. PLoS Neglected Tropical Diseases. 2017. doi:10.1371/journal.pntd.0005877 687 36. Aara N, Khandelwal K, Bumb RA, Mehta RD, Ghiya BC, Jakhar R, et al. Clinco-688 epidemiologic study of cutaneous leishmaniasis in bikaner, Rajasthan, India. Am J 689 Trop Med Hyg. 2013. doi:10.4269/ajtmh.12-0558 690 37. Simi S, Anish T, Jyothi R, Vijayakumar K, Philip R, Paul N. Searching for cutaneous 691 leishmaniasis in tribals from Kerala, India. J Glob Infect Dis. 2010. doi:10.4103/0974-692 777x.62874 693 38. PAHO. Leishmaniases - Epidemiological Report of the Americas - Nº4. 2016. 694 Drug for Neglected Disease Initiative. About Leishmaniasis - DNDi. 2019 [cited 31 39. 695 Dec 2019]. Available: https://www.dndi.org/diseases-projects/leishmaniasis/ 696 Leta S, Dao THT, Mesele F, Alemayehu G. Visceral Leishmaniasis in Ethiopia: An 697 40. Evolving Disease. PLoS Negl Trop Dis. 2014. doi:10.1371/journal.pntd.0003131 698 Neto AB da S, de Oliveira EF, Encina CCC, de Figueiredo HR, Filho ACP, de 699 41. Oliveira AG. Effects of El Niño-Southern oscillation on human visceral leishmaniasis 700 in the Brazilian State of Mato Grosso do Sul. Mem Inst Oswaldo Cruz. 2020;115: 1-8. 701 702 doi:10.1590/0074-02760190298 Deb RM, Stanton MC, Foster GM, Das Gupta RK, Roy N, Das P, et al. Visceral 703 42. leishmaniasis cyclical trends in Bihar, India - Implications for the elimination 704 705 programme. Gates Open Res. 2018. doi:10.12688/gatesopenres.12793.1 43. Johns Hopkins Bloomberg School of Public Health International Vaccine Access 706 Center (IVAC). A report on current global access to new childhood vaccines. 2019. 707

44. 708 Le Rutte EA, Coffeng LE, Malvolti S, Kaye PM, de Vlas SJ. The potential impact of human visceral leishmaniasis vaccines on population incidence. PLoS Negl Trop Dis. 709 2020;14: 1-13. doi:10.1371/journal.pntd.0008468 710 711 45. World Health Organization. MI4A - Market Information for Access to Vaccines. 2020. 46. Younis B, Osman M, Khalil E, Santoro F, Furini S, Wiggins R, et al. Safety and 712 713 immunogenicity of ChAd63-KH vaccine in post kala azar dermal leishmaniasis patients in Sudan. medRxiv. 2020; 2020.08.26.20180901. 714 715 doi:10.1101/2020.08.26.20180901 Romano A, Doria NA, Mendez J, Sacks DL, Peters NC. Cutaneous Infection with 47. 716 Leishmania major Mediates Heterologous Protection against Visceral Infection with 717 Leishmania infantum . J Immunol. 2015. doi:10.4049/jimmunol.1500752 718 719 48. Ramirez L, Corvo L, Duarte MC, Chávez-Fumagalli MA, Valadares DG, Santos DM, et al. Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal 720 protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral 721 leishmaniasis. Parasites and Vectors. 2014;7: 1-11. doi:10.1186/1756-3305-7-3 722 49. World Health Organization. Immunization Coverage. In: World Health Data Platform. 723 2020. 724 50. Hinman AR, Helms CM, Arvin AM, Freed GL, Guerra FA, Johnson DR, et al. 725 Financing vaccines in the 21st century: Recommendations from the National Vaccine 726 Advisory Committee. American Journal of Preventive Medicine. 2005. 727 doi:10.1016/j.amepre.2005.03.005 728 51. World Health Organization. Summary Measles SIA 2000-2020. 2020. 729 730 52. Rijal S, Sundar S, Mondal D, Das P, Alvar J, Boelaert M. Eliminating visceral leishmaniasis in South Asia: The road ahead. BMJ (Online). 2019. 731 732 doi:10.1136/bmj.k5224 James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, 733 53. regional, and national incidence, prevalence, and years lived with disability for 354 734 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic 735 analysis for the Global Burden of Disease Study 2017. Lancet. 2018. 736 doi:10.1016/S0140-6736(18)32279-7 737 738 54. World Bank. World Bank Country and Lending Groups - World Bank Data Help Desk. In: Country classification [Internet]. [cited 3 Jan 2020]. Available: 739 https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-740

741		country-and-lending-groups
742	55.	Snyder CM, Begor W, Berndt ER. Economic perspectives on the advance market
743		commitment for pneumococcal vaccines. Health Aff. 2011;30: 1508-1517.
744		doi:10.1377/hlthaff.2011.0403
745	56.	Olliaro PL, Kuesel AC, Halleux CM, Sullivan M, Reeder JC. Creative use of the
746		priority review voucher by public and not-for-profit actors delivers the first new FDA-
747		approved treatment for river blindness in 20 years. PLoS Negl Trop Dis. 2018;12: 10-
748		13. doi:10.1371/journal.pntd.0006837
749	57.	Jamka LP, Simiyu KW, Bentsi-Enchill AD, Mwisongo AJ, Matzger H, Marfin AA, et
750		al. Accelerating typhoid conjugate vaccine introduction: What can be learned from
751		prior new vaccine introduction initiatives? Clin Infect Dis. 2019.
752		doi:10.1093/cid/ciy1118
753	58.	Singh OP, Tiwary P, Kushwaha AK, Singh SK, Singh DK, Lawyer P, et al.
754		Xenodiagnosis to evaluate the infectiousness of humans to sandflies in an area
755		endemic for visceral leishmaniasis in Bihar, India: a transmission-dynamics study. The
756		Lancet Microbe. 2021;2: e23-e31. doi:10.1016/s2666-5247(20)30166-x
757	59.	Mo AX, Pesce J, Fenton Hall B. Meeting report: Visceral leishmaniasis control and
758		elimination: Is there a role for vaccines in achieving regional and global goals? Am J
759		Trop Med Hyg. 2016;95: 514–521. doi:10.4269/ajtmh.16-0184
760	60.	Engwerda CR, Matlashewski G. Development of Leishmania vaccines in the era of
761		visceral leishmaniasis elimination. Trans R Soc Trop Med Hyg. 2015;109: 423-424.
762		doi:10.1093/trstmh/trv039
763	61.	Matlashewski G, Arana B, Kroeger A, Be-Nazir A, Mondal D, Nabi SG, et al.
764		Research priorities for elimination of visceral leishmaniasis. Lancet Glob Heal.
765		2014;2: e683-e684. doi:10.1016/S2214-109X(14)70318-3
766	62.	Sundar S, Singh OP, Chakravarty J. Visceral leishmaniasis elimination targets in India,
767		strategies for preventing resurgence. Expert Review of Anti-Infective Therapy. 2018.
768		doi:10.1080/14787210.2018.1532790
769		
770		

Clinical	Species /	Goal	Use case	Rationale
vL	geographies L. donovani/infantum All geographies	Prophylactic	a. VL prophylaxis	Broader impact
	001	Therapeutic for HIV+	2 <sup>nd</sup> line treatment of VL in HIV+	Deprioritized in view of the difficulty of treatment
PKDL	South Asia and East Africa	Preventive	Prevention of VL relapse (PKDL)	Seriousness of the diseases
		Therapeutic	1 <sup>st</sup> line treatment of PKDL	
CL	L. tropica/aethiopica East Africa and Middle East*	Prophylactic Therapeutic	b. CL prophylaxis c. 1 <sup>st</sup> line treatment of CL	Poor available treatment, uncontrolled
	<i>L. (Viannia)</i> <i>braziliensis</i> Brazil / Americas	Prophylactic Therapeutic	d. CL prophylaxis e. 1 <sup>st</sup> line treatment of CL	Morbidity can be addressed through treatment
	Other species	Prophylactic	CL prophylaxis	Deprioritised in view of the limited size of the target population
		Therapeutic	1 <sup>st</sup> line treatment of CL	
MCL- DSL-DCL	All species	Therapeutic	m. 1 <sup>st</sup> line treatment of MCL-DSL-DCL	Deprioritised in view of the limited size of the target population

# 773 Table 1 – Leishmaniasis vaccine use cases definition and prioritisation

Use case	Species / geographies	Delivery strategy/ies
1. Prevention of VL	All geographies	Routine or campaign delivery in target at-risk populations (identified via endemicity mapping) Outbreak response via ring vaccination
2. Prevention of CL	All geographies	Routine or campaign delivery in target at-risk populations (identified via endemicity mapping)
3. Prevention of PKDL	All geographies	Adjunct(following) VL treatment
4. Treatment of PKDL		Same as current PKDL treatments

# 777 Table 2 - Final set of use cases and delivery strategies

Indication	Target Population	Range	Sources	2018
Prevention of VL	Population at risk of VL	Upper limit	WHO country estimates for 2014-15 and Pigott 2014	665,000,000
		Mid-point (base case)	WHO TRS 2010	404,000,000
		Lower limit	DNDi 2009	235,000,000
Prevention of	Population	Upper limit	DNDi 2018	1,000,000,000
CL	at risk of	Mid-point	WHO country estimates	778,000,000
	CL*	(base case)	for 2014-15 and Pigott 2014	
		Lower limit	WHO TRS 2010	392,000,000
Prevention of	VL cases	Upper limit	GBD, 2017, WER 2018,	17,326
PKDL		Mid-point (base case)	Alavar 2012	13,800
		Lower limit	-	9,784
Treatment of	PKDL	Upper limit	WER 2018, Alavar 2012	4,437
PKDL	cases	Mid-point (base case)	with disease specific assumptions from Zijstra	3,462
		Lower limit	2016, Kaye 2019, Mondel 2018	2,382

779

780 Table 3: Target population \*30% of this population is assumed being also at risk of VL

# 


Indication	Age for first dose	Duration of Protection	Nr. Doses per Series	Series (years of age)
VL	1 year	5 years	2	3
prophylactic				(1, 6 and 11)
CL	1 year	5 years	2	3
prophylactic				(1, 6 and 11)
CL/VL catch-			2	1
up				
PKDL	NA	Lifelong	1	1
therapeutic				
PKDL preventive	NA	Lifelong	1	1


784Table 4 : Selected TPP assumptions relevant for the demand forecast

Indication	Delivery	Coverage
VL & CL prophylactic	Routine at 9 months-2 <sup>nd</sup> year of life	73%
	Routine at 6 years – 11 years	68%
	Routine for adults	45%
	Campaign delivery (including catch-up)	90%
PKDL therapeutic &	Following delivery of VL or PKDL	93%
preventive	treatment	

786

- 787 Table 5: Delivery strategy and related coverage assumptions (source: WHO/UNICEF
- coverage estimates for 2018, WHO Measles campaign overview 2000-2020)







808 Figure 2: Vaccine demand – total number of yearly doses required at global level for a

809 vaccine with VL and CL indications (details of the methodology provided in the

810 **Supplementary Annex**)



- 824 Figure 3: Vaccine demand: total number of doses for the period 2025-2040 stratified by
- 825 delivery strategy (routine immunisation and catch-up campaign at start) and by
- 826 indication (VL and CL)



839 Figure 4: Vaccine demand – total number of yearly doses required at global level for a

- 840 vaccine with PKDL therapeutic and preventative indications (in the scenario of a
- 841 vaccine with VL indication also being available)
- 842
- 843